No abstract

Given the marginal benefit of standard chemotherapy in most STS and the poor outcomes of many of these patients, there is a critical need to identify novel therapies. Biology studies to identify important pathways and therapeutic targets will be key, as will histology-specific clinical trials. We agree with Ferrari that future progress in pediatric NRSTS depends on eliminating the obstacles preventing combined pediatric-adult STS studies. Differing treatment considerations may make collaborative pediatric-adult STS clinical trials challenging, but these issues should not be prohibitive. We look forward to joining Ferrari, Baker 7 , and others in designing future collaborative studies for adults and children with STS.

No abstract